Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
- 27 January 2017
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 20 (4), 520-532
- https://doi.org/10.1016/j.jval.2016.12.003
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- METHODOLOGICAL CHALLENGES IN EVALUATING THE VALUE OF REGISTERSInternational Journal of Technology Assessment in Health Care, 2014
- Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?Therapies, 2013
- The Italian post-marketing registriesPharmaceutical Programming, 2012
- Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug responseNature Reviews Drug Discovery, 2011
- Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trialsJournal of Clinical Epidemiology, 2010
- Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experienceEuropean Journal of Clinical Investigation, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groupsInternational Journal for Quality in Health Care, 2007
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- Three Approaches to Qualitative Content AnalysisQualitative Health Research, 2005